Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (171-180 of 387) with videos related to

Pageof 39
Sort By:
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Blood Cancer Journal|January 8, 2021
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphomaAlessia Castellino, Aung M Tun, Yucai Wang, et al.
Blood|August 13, 2009
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cellsRyan A Wilcox, David A Wada, Steven C Ziesmer, et al.
JCO Oncology Practice|February 26, 2024
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With LymphomaHuong L Truong, Jason N Barreto, Kristin C Mara, et al.
Haematologica|August 30, 2023
Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapyZhuoer Xie, Terra Lasho, Arushi Khurana, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
Redox Biology|August 9, 2020
Increased glutathione utilization augments tumor cell proliferation in Waldenstrom MacroglobulinemiaShahrzad Jalali, Jie Shi, Alex Buko, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 4, 2012
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesEsteban Braggio, Ahmet Dogan, Jonathan J Keats, et al.
Cancer Research|April 23, 2009
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphomaAnne J Novak, Susan L Slager, Zachary S Fredericksen, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Pageof 39

Showing results (171-180 of 387) with videos related to

Sort By:
Pageof 39
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Blood Cancer Journal|January 8, 2021
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphomaAlessia Castellino, Aung M Tun, Yucai Wang, et al.
Blood|August 13, 2009
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cellsRyan A Wilcox, David A Wada, Steven C Ziesmer, et al.
JCO Oncology Practice|February 26, 2024
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With LymphomaHuong L Truong, Jason N Barreto, Kristin C Mara, et al.
Haematologica|August 30, 2023
Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapyZhuoer Xie, Terra Lasho, Arushi Khurana, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
Redox Biology|August 9, 2020
Increased glutathione utilization augments tumor cell proliferation in Waldenstrom MacroglobulinemiaShahrzad Jalali, Jie Shi, Alex Buko, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 4, 2012
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesEsteban Braggio, Ahmet Dogan, Jonathan J Keats, et al.
Cancer Research|April 23, 2009
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphomaAnne J Novak, Susan L Slager, Zachary S Fredericksen, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Pageof 39